REALASA: Real-world effectiveness assessment of first-line 5-ASA for the treatment of Ulcerative Colitis in Sweden

被引：0

作者：

Christophersen, B. ^{[1
]}

Nielsen, L. ^{[2
]}

Landeira, M. ^{[3
]}

Guedes, S. ^{[4
]}

机构：

[1] Ferring Pharmaceut Inc, Med Affairs, Copenhagen, Denmark

[2] Ferring Pharmaceut Inc, Stat, Copenhagen, Denmark

[3] Ferring Pharmaceut Inc, Hlth Econ & Outcomes Res, Copenhagen, Denmark

[4] Ferring Pharmaceut Inc, Real World Evidence, Copenhagen, Denmark

来源：

JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷

关键词：

D O I：

10.1093/ecco-jcc/jjae190.0907

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P0733

引用

页码：I1423 / I1423

页数：1

共 50 条

[21] A REAL-WORLD COMPARISON OF THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND ANTI-TNF THERAPIES IN EARLY TREATMENT INITIATION WITH FIRST-LINE BIOLOGIC THERAPY IN ULCERATIVE COLITIS: RESULTS FROM EVOLVE
Mantzaris, Gerassimos J.
Bressler, Brian
Kopylov, Uri
Bassel, Marielle
Brett, Neil R.
Colby, Chris
Lopez, Claudia
Saha, Sumit
Kifnidi, Christina
Agboton, Christian
Adsul, Shashi
Demuth, Dirk
Luo, Michelle
Wang, Song
Yarur, Andres J.
GASTROENTEROLOGY, 2020, 158 (06) : S405 - S405
[22] Impact of Real-World Adherence on Effectiveness of First-Line DMTs in Multiple Sclerosis
Agashivala, Neetu
Raimundo, Karina
Kim, Edward
Brandes, David
NEUROLOGY, 2013, 80
[23] Cost-effectiveness of sulfasalazine vs 5-ASA in the maintenance of remission of chronic ulcerative colitis (CUC).
Leighton, JA
Ramzan, NN
Pasha, TM
GASTROENTEROLOGY, 1999, 116 (04) : A74 - A74
[24] Baseline gut microbiota composition and function reflect response to 5-ASA treatment in Ulcerative Colitis
Radhakrishnan, S. T.
Alexander, J. L.
Mullish, B. H.
Danckert, N. P.
Valdivia-Garcia, M. A.
Serrano-Contreras, J. I.
Balarajah, S.
Perry, R.
Gallagher, K. I.
Hicks, L. C.
Powell, N.
Li, J. V.
Marchesi, J. R.
Williams, H. R. T.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I2138 - I2138
[25] TOPICAL TREATMENT OF REFRACTORY DISTAL ULCERATIVE-COLITIS WITH 5-ASA AND SODIUM-BUTYRATE
VERNIA, P
CITTADINI, M
CAPRILLI, R
TORSOLI, A
DIGESTIVE DISEASES AND SCIENCES, 1995, 40 (02) : 305 - 307
[26] Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis
Louis, Edouard
Paridaens, Kristine
Al Awadhi, Sameer
Begun, Jakob
Cheon, Jae Hee
Dignass, Axel U.
Magro, Fernando
Marquez, Juan Ricardo
Moschen, Alexander R.
Narula, Neeraj
Rydzewska, Grazyna
Freddi, Matthew J.
Travis, Simon Pl
BMJ OPEN GASTROENTEROLOGY, 2022, 9 (01):
[27] MESALAZINE (5-ASA) VERSUS SULFASALAZINE (SASP) IN THE MAINTENANCE TREATMENT OF PATIENTS WITH ULCERATIVE-COLITIS
SPIES, SK
BUCHEL, EH
ELOFF, FP
SOUTH AFRICAN MEDICAL JOURNAL, 1988, 73 (11): : 668 - 668
[28] Measurements of tissue 5-ASA concentration in the colonic mucosa is useful for predicting its effectiveness in the treatment of distal ulcerative colitis.
Naganuma, M
Iwao, Y
Inoue, N
Funakoshi, S
Yamamoto, S
Nakamura, Y
Ishii, H
Kanai, T
Watanabe, M
Hibi, T
GASTROENTEROLOGY, 2000, 118 (04) : A780 - A780
[29] Acute pericarditis associated with 5-aminosalicylic acid (5-ASA) treatment for severe active ulcerative colitis
Ishikawa, N
Imamura, T
Nakajima, K
Yamaga, J
Yuchi, H
Ootsuka, M
Inatsu, H
Aoki, T
Eto, T
INTERNAL MEDICINE, 2001, 40 (09) : 901 - 904
[30] REAL-WORLD EFFECTIVENESS AND SAFETY OF OZANIMOD IN ULCERATIVE COLITIS: A MULTICENTER STUDY
Lieto, Stephen
Scalzo, Nicholas
Huang, Katherine
Khan, Abdul
Xu, Anthony
Pekow, Joel
Rajauria, Palak
Ayoub, Malek
Johnson, Amanda M.
Yarur, Andres
Patel, Anish
Bishu, Shrinivas
Shukla, Richa
Osterman, Mark T.
Paul, Damemarie
Sokol, Uyen
Tharmarajah, Soba
Lawlor, Garrett
Ahmad, Harris
Rubin, David T.
Sands, Bruce E.
Deepak, Parakkal
Ungaro, Ryan C.
GASTROENTEROLOGY, 2024, 166 (05) : S1455 - S1456

← 1 2 3 4 5 →